Shradha Banerjee

Shradha Banerjee

Auto-generated profile, based on publicly available information

Shradha Banerjee

Royal College Port Louis, Port Louis, Mauritius

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 October 2026 in Nepal Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
IBIndrajit Banerjee
Indrajit Banerjee
KMKrissheeven Mooroogiah
Krissheeven Mooroogiah
JRJared Robinson
Jared Robinson
NPNishant Pandey
Nishant Pandey
SBShradha Banerjee
Shradha Banerjee
IBIndraneel Bannerjee
Indraneel Bannerjee
Background: Polyendocrine metabolic ovarian syndrome (PMOS), formerly referred to as polycystic ovary syndrome (PCOS), is among the most common endocrine disorders in women of reproductive age. Methods: An extensive literature search was done on Cochrane, PubMed, TRIP and Google Scholar. Pooled effect estimates were calculated using a fixed-effect model (I250 %). Result: The combination of metformin and liraglutide was associated with significantly lower fasting blood glucose level as compared to mono-therapy [MD]= -0.19 mmol/L, 95% CI: -0.33-0.06 mmol/l, Z=2.79, P=0.005, χ²=6.08, df=3, P=0.11, I2=0%). The combination of drugs significantly increased sex hormone binding globulin as compared to monotherapy [MD]= 7.89L, 95% CI 3.80-11.99, Z=3.78, P=0.0002, χ²=1.74, df=1, P=0.19, I2=42%). The pooled analysis demonstrated that metformin significantly reduced the risk of nausea as compared to the Metformin and liraglutide combination (RR=8.30 95% CI: 2.64, 26.10, Z=3.62, P=0.0003, χ²=0.43, df=2, p=0.80, I2 =0%). Conclusion: The combination of liraglutide and metformin was found to be advantageous over metformin in monotherapy, with respect to improving the patient’s glycaemic control by inducing a significant reduction in the fasting blood glucose level as compared to monotherapy. The combination therapy also significantly increased sex hormone binding globulin, such hormonal control is an underpinning facet in the treatment of PMOS and therefore this finding advocates for the use of metformin and liraglutide in combination.

5 October 2026 in Nepal Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
IBIndrajit Banerjee
Indrajit Banerjee
JRJared Robinson
Jared Robinson
KMKrissheeven Mooroogiah
Krissheeven Mooroogiah
NPNishant Pandey
Nishant Pandey
SBShradha Banerjee
Shradha Banerjee
IBIndraneel Banerjee
Indraneel Banerjee
Tavapadon is a novel, highly selective D1/D5 partial dopamine agonist with little activity at D2/D3 receptors. This systematic review was undertaken to assess the efficacy and safety of tavapadon in Parkinson’s disease and to better define its overall therapeutic potential. Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines were implemented during the conduct of this systematic review and were prospectively registered with the International Prospective Register of Systematic Reviews (PROSPERO) under registration number CRD420261489191. All RCTs on Tavapadon in Pakinsons disease from 2010 to 2026 were searched and evaluated against specific eligibility criteria and were included in this systematic review. The part III MDS-UPDRS ranged from -9.0 to 11 for Tavapadon and from -4.3 to 4.6 for placebo. For part I MDS-UPDRS, Tavapadon ranged from -0.2 to 1.4 and Placebo ranged from 0 to 1. Part II and part III combined MDS-UPDRS, Tavapadon ranged from -10.3 to 10.3 and placebo ranged from -1.2 to 4.7. Tavapadon showed more adverse effects compared to placebo viz. nausea, headache, dry mouth, tremors, constipation, dyspepsia, salivary hypersecretion, fatigue, dizziness and hallucinations whereas placebo showed more tremors. It is evident that the novel drug Tavapadon has shown improved motor as well as Unified Parkinson's Disease Rating Scale scores as when compared to the placebo. Similarly Tavapadon has also shown to have a host of side effects which are expected in drugs acting on the dopaminergic receptors. Further investigation will be needed to take place in order to establish the clinical efficacy as well as the adverse effects profile of Tavapadon and traditional Dopaminergic drugs in head to head comparison studies.

2 April 2026 in Nepal Journal of Epidemiology
Verified
Journal Article
Open access
JRJared Robinson
Jared Robinson
SBShradha Banerjee
Shradha Banerjee
DRDoané Robinson
Doané Robinson
IBIndraneel Banerjee
Indraneel Banerjee
Cardiovascular disease is the leading cause of mortality worldwide, claiming the lives of roughly 18 million individuals annually. MicroRNAs have been found to have a highly active role in the pathogenesis and progression of Cardiovascular disease. The top 10 studied MicroRNAs in cardiovascular disease are namely miR-1, miR-208, miR-21, miR-29, miR-126, miR-145, miR-133, miR-155, miR-30 and miR-499.The potential and the development of the use of MicroRNAs will open up a new frontier in molecular cardiology and will further expand the frontier of precision medicine. MicroRNAs are almost limitless in their capabilities therapeutically, as they can be mimicked or inhibited, depending on their specific mechanism. It is evident that microRNAs will be a vital tool that both saves a countless number of lives as well as aids in reducing the mortality and morbidity in patients suffering from chronic diseases, most specifically in cardiovascular diseases. Their clinical and therapeutic potential are almost limitless and will someday be a mainstay in patient management and treatment.

31 December 2025 in Journal of Biomedical Sciences
Verified
Journal Article
Open access
NJNavita Jatain
Navita Jatain
RSRudraksh Sharma
Rudraksh Sharma
SBShradha Banerjee
Shradha Banerjee
KDKrishna Dodia
Krishna Dodia
SDSanjay Kumar Deshwali
Sanjay Kumar Deshwali
IBIndrajit Banerjee
Indrajit Banerjee
Background: The primary objective of the study was to identify the motivational factors influencing the choice of medicine among first-year medical students to become doctors in Mauritius. Material and methods: A mixed-methods cross-sectional study was conducted at Sir Seewoosagur Ramgoolam Medical College, Mauritius, in November 2025. Results: Of the 140 medical students enrolled in the first-year medical course, 110 students participated in the study, yielding an overall response rate of 78.57% (50 female, 45.45%; 60 male, 54.54%). Most were Mauritian (n=63, 57.2%), followed by Indian (n=35, 31.8%) and South African (n=11, 10.0%) students. Altruism was the most commonly reported motivation for choosing medicine. Specialty preference differed significantly by gender (χ²=15.73, p=0.008): females more often preferred Paediatrics and Obstetrics and Gynaecology, whereas males more often preferred Surgery. Students with a family member in healthcare were more likely to report prior exposure (χ²=4.97, p=0.026), but family attitudes were not significantly associated with perceived preparedness (χ²=10.28, p=0.246). An inductive thematic analysis was conducted for the qualitative domain, and two themes were generated from various codes/nodes: namely Intrinsic factors and Extrinsic factors. Each theme had different categories. Conclusion: Medical students’ choice to pursue medicine was primarily driven by intrinsic motivations, particularly altruism, compassion, and a sense of calling. While extrinsic factors such as career stability, financial security, and social status also influence decision-making, they function as a reinforcing influence rather than primary driving forces.